Positive Phase 2a Data Demonstrates Improved Outcomes With a 2-Dose Induction Regimen of BPL-003 in Patients With Treatment-Resistant Depression
A phase 2a trial evaluated BPL-003, an intranasal formulation of mebufotenin benzoate, in patients with treatment-resistant depression not receiving...